Jefferies downgraded Esperion (ESPR) to Hold from Buy with a price target of $3.28, down from $5, after the company announced it will be acquired by Archimed for $3.16 per share and a $100M contingent value right. The sees this as “a good outcome” ahead of major competitive headwinds over the next 6-18 months, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ESPR:
- Esperion downgraded to Neutral from Overweight at Piper Sandler
- Esperion agrees to $1.1 billion ARCHIMED buyout
- Midday Fly By: Apple reports Q2 beat, oil majors post mixed results
- Esperion downgraded to Neutral from Buy at H.C. Wainwright
- Esperion downgraded to Neutral from Overweight at Cantor Fitzgerald